FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200427912> ?p ?o ?g. }

• W4200427912 endingPage "133" @default.
• W4200427912 startingPage "133" @default.
• W4200427912 abstract "Decreases in future lung function are a hallmark of preterm birth, but studies for management of decreased lung function are limited.To determine whether 12 weeks of treatment with inhaled corticosteroids (ICS) alone or in combination with long-acting β2 agonists (LABA) improves spirometry and exercise capacity in school-aged preterm-born children who had percent predicted forced expiratory volume in 1 second (%FEV1) less than or equal to 85% compared with inhaled placebo treatment.A double-blind, randomized, placebo-controlled trial was conducted to evaluate ICS and ICS/LABA against placebo. Preterm-born children (age, 7-12 years; gestation ≤34 weeks at birth) who did not have clinically significant congenital, cardiopulmonary, or neurodevelopmental abnormalities underwent spirometry, exercise testing, and measurement of fractional exhaled nitric oxide before and after treatment. A total of 144 preterm-born children at the Children's Hospital for Wales in Cardiff, UK, were identified and enrolled between July 1, 2017, and August 31, 2019.Each child was randomized to 1 of 3 cohorts: fluticasone propionate, 50 μg, with placebo; fluticasone propionate, 50 μg, with salmeterol, 25 μg; or placebo inhalers, all given as 2 puffs twice daily for 12 weeks. Children receiving preexisting ICS treatment underwent washout prior to randomization to ICS or ICS/LABA.The primary outcome was between-group differences assessed by adjusted pretreatment and posttreatment differences of %FEV1 using analysis of covariance. Intention-to-treat analysis was conducted.Of 144 preterm-born children who were identified with %FEV1 less than or equal to 85%, 53 were randomized. Treatment allocation was 20 children receiving ICS (including 5 with prerandomization ICS), 19 children receiving ICS/LABA (including 4 with prerandomization ICS), and 14 children receiving placebo. The mean (SD) age of children was 10.8 (1.2) years, and 29 of the randomized children (55%) were female. The posttreatment %FEV1 was adjusted for sex, gestation, bronchopulmonary dysplasia, intrauterine growth restriction, pretreatment corticosteroid status, treatment group, and pretreatment values. Posttreatment adjusted means for %FEV1, using analysis of covariance, were 7.7% (95% CI, -0.27% to 15.72%; P = .16) higher in the ICS group and 14.1% (95% CI, 7.3% to 21.0%; P = .002) higher in the ICS/LABA group compared with the placebo group. Active treatment decreased the fractional exhaled nitric oxide and improved postexercise bronchodilator response but did not improve exercise capacity. One child developed cough when starting inhaler treatment; no other adverse events reported during the trial could be attributed to the inhaler treatment.The results of this randomized clinical trial suggest that combined ICS/LABA treatment is beneficial for prematurity-associated lung disease in children.EudraCT number: 2015-003712-20." @default.
• W4200427912 created "2021-12-31" @default.
• W4200427912 creator A5001682249 @default.
• W4200427912 creator A5003432782 @default.
• W4200427912 creator A5031453176 @default.
• W4200427912 creator A5046396554 @default.
• W4200427912 creator A5047856414 @default.
• W4200427912 creator A5054312557 @default.
• W4200427912 creator A5061435396 @default.
• W4200427912 creator A5067149532 @default.
• W4200427912 creator A5075808422 @default.
• W4200427912 creator A5081343591 @default.
• W4200427912 date "2022-02-01" @default.
• W4200427912 modified "2023-10-01" @default.
• W4200427912 title "Inhaled Corticosteroids Alone and in Combination With Long-Acting β₂ Receptor Agonists to Treat Reduced Lung Function in Preterm-Born Children" @default.
• W4200427912 cites W1857644434 @default.
• W4200427912 cites W1967505834 @default.
• W4200427912 cites W1969536852 @default.
• W4200427912 cites W1975124845 @default.
• W4200427912 cites W1992374778 @default.
• W4200427912 cites W1994543950 @default.
• W4200427912 cites W1997236105 @default.
• W4200427912 cites W2036520838 @default.
• W4200427912 cites W2059049556 @default.
• W4200427912 cites W2104500646 @default.
• W4200427912 cites W2120653858 @default.
• W4200427912 cites W2160310657 @default.
• W4200427912 cites W2168233902 @default.
• W4200427912 cites W2393080350 @default.
• W4200427912 cites W2400545813 @default.
• W4200427912 cites W2903989115 @default.
• W4200427912 cites W2944689947 @default.
• W4200427912 cites W2975374603 @default.
• W4200427912 cites W3204459479 @default.
• W4200427912 cites W4242763225 @default.
• W4200427912 cites W4244422496 @default.
• W4200427912 cites W4248251600 @default.
• W4200427912 cites W4253071530 @default.
• W4200427912 doi "https://doi.org/10.1001/jamapediatrics.2021.5111" @default.
• W4200427912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34902004" @default.
• W4200427912 hasPublicationYear "2022" @default.
• W4200427912 type Work @default.
• W4200427912 citedByCount "19" @default.
• W4200427912 countsByYear W42004279122022 @default.
• W4200427912 countsByYear W42004279122023 @default.
• W4200427912 crossrefType "journal-article" @default.
• W4200427912 hasAuthorship W4200427912A5001682249 @default.
• W4200427912 hasAuthorship W4200427912A5003432782 @default.
• W4200427912 hasAuthorship W4200427912A5031453176 @default.
• W4200427912 hasAuthorship W4200427912A5046396554 @default.
• W4200427912 hasAuthorship W4200427912A5047856414 @default.
• W4200427912 hasAuthorship W4200427912A5054312557 @default.
• W4200427912 hasAuthorship W4200427912A5061435396 @default.
• W4200427912 hasAuthorship W4200427912A5067149532 @default.
• W4200427912 hasAuthorship W4200427912A5075808422 @default.
• W4200427912 hasAuthorship W4200427912A5081343591 @default.
• W4200427912 hasBestOaLocation W42004279121 @default.
• W4200427912 hasConcept C126322002 @default.
• W4200427912 hasConcept C142724271 @default.
• W4200427912 hasConcept C168563851 @default.
• W4200427912 hasConcept C187212893 @default.
• W4200427912 hasConcept C204243189 @default.
• W4200427912 hasConcept C204787440 @default.
• W4200427912 hasConcept C27081682 @default.
• W4200427912 hasConcept C2776042228 @default.
• W4200427912 hasConcept C2776719499 @default.
• W4200427912 hasConcept C2776804153 @default.
• W4200427912 hasConcept C2779028295 @default.
• W4200427912 hasConcept C2780333948 @default.
• W4200427912 hasConcept C2781018748 @default.
• W4200427912 hasConcept C2781142857 @default.
• W4200427912 hasConcept C2781212218 @default.
• W4200427912 hasConcept C42219234 @default.
• W4200427912 hasConcept C71924100 @default.
• W4200427912 hasConceptScore W4200427912C126322002 @default.
• W4200427912 hasConceptScore W4200427912C142724271 @default.
• W4200427912 hasConceptScore W4200427912C168563851 @default.
• W4200427912 hasConceptScore W4200427912C187212893 @default.
• W4200427912 hasConceptScore W4200427912C204243189 @default.
• W4200427912 hasConceptScore W4200427912C204787440 @default.
• W4200427912 hasConceptScore W4200427912C27081682 @default.
• W4200427912 hasConceptScore W4200427912C2776042228 @default.
• W4200427912 hasConceptScore W4200427912C2776719499 @default.
• W4200427912 hasConceptScore W4200427912C2776804153 @default.
• W4200427912 hasConceptScore W4200427912C2779028295 @default.
• W4200427912 hasConceptScore W4200427912C2780333948 @default.
• W4200427912 hasConceptScore W4200427912C2781018748 @default.
• W4200427912 hasConceptScore W4200427912C2781142857 @default.
• W4200427912 hasConceptScore W4200427912C2781212218 @default.
• W4200427912 hasConceptScore W4200427912C42219234 @default.
• W4200427912 hasConceptScore W4200427912C71924100 @default.
• W4200427912 hasIssue "2" @default.
• W4200427912 hasLocation W42004279121 @default.
• W4200427912 hasLocation W42004279122 @default.
• W4200427912 hasLocation W42004279123 @default.
• W4200427912 hasLocation W42004279124 @default.
• W4200427912 hasLocation W42004279125 @default.
• W4200427912 hasOpenAccess W4200427912 @default.

• next